{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:06:58Z","timestamp":1788314818866,"version":"build-2803163510"},"update-to":[{"DOI":"10.12688\/f1000research.125944.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000}}],"reference-count":18,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>\n                    <ns3:bold>Background<\/ns3:bold>\n                    : Preeclampsia is a highly prevalent disease among pregnant women. In the event of hypertensive emergency, nifedipine, labetalol, and hydralazine are assigned as first-line therapies in preeclampsia. Further studies are needed to compare the effectiveness of these drugs to find the most cost-effective drug with minimal side effects. This study aimed to compare the effectiveness of these drugs in lowering blood pressure during hypertensive emergencies in severe preeclampsia.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Methods<\/ns3:bold>\n                    : 60 pregnant women with severe preeclampsia were recruited in this multiple centre double-blind randomized clinical trial from May 2021 to April 2022 in Indonesia. The patients were divided equally into three groups and treated with three doses of nifedipine, labetalol, and hydralazine, respectively within one hour with 20 minutes interval. The effectiveness was measured based on systolic and diastolic blood pressures, and mean arterial pressure (MAP). The observation was carried out until five hours post-third dose administration. \u00a0\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Results<\/ns3:bold>\n                    : The blood pressure was reduced significantly after the administration of the first to the third dose of each antihypertensive (p&lt;0.05). A single dose administration, four, one, and three patients had 20% MAP reduction in nifedipine, labetalol, and hydralazine group. Three, seven, and one patient had a failure of reaching 20% MAP reduction even after receiving the third dose. The effectiveness of the drugs to achieve 20% reduction of MAP could be ranked as follows: nifedipine&gt;labetalol&gt;hydralazine (57.49%, 42.13%, and 40.87%, respectively) for single dose and hydralazine&gt;nifedipine&gt;labetalol (111.3%, 85.12%, and 90.04%, respectively) for triple dose.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Conclusions<\/ns3:bold>\n                    : Nifedipine is the most effective drug to reduce the blood pressure when single dose administration is used, but requires more doses to further reduce the blood pressure. Hydralazine is the most effective when the drug administration is maxed up to three doses within 60 minutes with 20 minutes interval.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Thai Clinical Trials Registry (TCTR):<\/ns3:bold>\n                    <ns3:ext-link xmlns:ns4=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" ns4:href=\"https:\/\/www.thaiclinicaltrials.org\/show\/TCTR20221014007\">TCTR20221014007<\/ns3:ext-link>\n                    (14\/10\/2022)\n                  <\/ns3:p>","DOI":"10.12688\/f1000research.125944.2","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T10:05:08Z","timestamp":1682589908000},"page":"1287","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial"],"prefix":"10.12688","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-3551","authenticated-orcid":false,"given":"Donel","family":"S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhini Aiyulie","family":"Novri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3412-4063","authenticated-orcid":false,"given":"Yulis","family":"Hamidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-030X","authenticated-orcid":false,"given":"Maya","family":"Savira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"ref1","article-title":"Gestational Hypertension and Preeclampsia. Practice Bulletin No. 222, June 2020."},{"key":"ref2","article-title":"Emergent therapy for acute onset, severe hypertension during pregnancy and the postpartum period.","year":"Feb 2019","journal-title":"Committee Opinion."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"376-381","DOI":"10.1007\/s13224-017-1053-9","article-title":"Comparison of Efficacy and Safety of Intravenous Labetalol Versus Hydralazine for Management of Severe Hypertension in Pregnancy.","volume":"68","author":"P Patel","year":"2018","journal-title":"J. Obstet. Gynaecol. India."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1011-1021","DOI":"10.1016\/S0140-6736(19)31282-6","article-title":"Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.","volume":"394","author":"T Easterling","year":"2019","journal-title":"Lancet."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1259-1268","DOI":"10.1119\/1.1514215","article-title":"The relationship between mathematics preparation and conceptual learning gains in physics: A possible \u201chidden variable\u201d in diagnostic pretest scores.","volume":"70","author":"D Meltzer","year":"2002","journal-title":"Am. J. Phys."},{"key":"ref8","article-title":"Analyzing change\/gain scores.","author":"R Hake","year":"1999"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"25-29","DOI":"10.3329\/fmcj.v16i1.55733","article-title":"Oral Nifedipine versus Intravenous Labetalol for Acute Blood Pressure Control in Severe Hypertension of Pregnancy: A Study at Faridpur Medical College Hospital.","volume":"16","author":"S Biswas","year":"2021","journal-title":"Faridpur Med. Coll. J."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"78-85","DOI":"10.1111\/j.1471-0528.2011.03151.x","article-title":"Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial.","volume":"119","author":"I Raheem","year":"2012 Jan","journal-title":"BJOG."},{"key":"ref11","first-page":"42-46","article-title":"A randomized trial of intravenous labetalol & oral nifedipine in severe pregnancy induced hypertension.","volume":"1","author":"B Dhali","year":"2012","journal-title":"Int. J. Reprod. Contracept. Obstet. Gynecol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e21-e41","DOI":"10.1161\/HYP.0000000000000208","article-title":"Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association.","volume":"79","author":"V Garovic","year":"2022","journal-title":"Hypertension."},{"key":"ref13","first-page":"701-706","article-title":"Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy.","volume":"49","author":"Z Rezaei","year":"2011","journal-title":"Acta Med. Iran."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1011-1021","DOI":"10.1016\/S0140-6736(19)31282-6","article-title":"Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.","volume":"394","author":"T Easterling","year":"2019 Sep 21","journal-title":"Lancet."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"177-186","DOI":"10.1016\/j.preghy.2020.01.011","article-title":"The flipside of hydralazine in pregnancy: A systematic review and meta-analysis.","volume":"19","author":"C Antza","year":"2020 Jan","journal-title":"Pregnancy Hypertens."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1210-1218","DOI":"10.1111\/1471-0528.12737","article-title":"Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review.","volume":"121","author":"T Firoz","year":"2014 Sep","journal-title":"BJOG."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"317-324","DOI":"10.4103\/npmj.npmj_275_20","article-title":"Efficacy of nifedipine versus hydralazine in the management of severe hypertension in pregnancy: A randomised controlled trial.","volume":"27","author":"J Adebayo","year":"2020 Oct-Dec","journal-title":"Niger. Postgrad. Med. J."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"25-30","DOI":"10.1034\/j.1600-0412.2002.810105.x","article-title":"Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia.","volume":"81","author":"B Aali","year":"2002 Jan","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.20933785.v2","author":"D Suhaimi","year":"2022","journal-title":"Journal Contribution."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.21443028.v1","author":"D Suhaimi","year":"2022","journal-title":"Journal Contribution."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/11-1287\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/11-1287\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/11-1287\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T09:21:57Z","timestamp":1685697717000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/11-1287\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":18,"URL":"https:\/\/doi.org\/10.12688\/f1000research.125944.2","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.144510.r171163","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.144510.r171164","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.144510.r171164","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.144510.r171163","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/11-1287\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.144510.r171163, Talha Bin Emran, Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, 02 May 2023, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/11-1287\/v2#referee-response-171163","order":0,"name":"referee-response-171163","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.144510.r171164, Jon Wantania, Windy Wariki, Department of Obstetric and Gynaecology, Maternal Foetal Medicine Division, Medical Faculty, Sam Ratulangi University, Manado, North Sulawesi, 02 Jun 2023, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/11-1287\/v2#referee-response-171164","order":1,"name":"referee-response-171164","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}